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Background: Spain, a Mediterranean country with relatively low rates of coronary heart disease, has a high
prevalence of traditional cardiovascular risk factors and is experiencing a severe epidemic of overweight/obesity. We
designed the Aragon Workers’ Health Study (AWHS) to characterize the factors associated with metabolic
abnormalities and subclinical atherosclerosis in a middle aged population in Spain free of clinical cardiovascular
disease. The objective of this paper is to describe the study design, aims and baseline characteristics of participants
in the AWHS.
Methods/Design: Longitudinal cohort study based on the annual health exams of 5,400 workers of a car assembly
plant in Figueruelas (Zaragoza, Spain). Study participants were recruited during a standardized clinical exam in
2009–2010 (participation rate 95.6%). Study participants will undergo annual clinical exams and laboratory assays,
and baseline and triennial collection of biological materials for biobanking and cardiovascular imaging exams
(carotid, femoral and abdominal ultrasonography, coronary calcium score, and ankle-arm blood pressure index).
Participants will be followed-up for 10 years.
Results: The average (SD) age, body mass index, and waist circumference were 49.3 (8.7) years, 27.7 (3.6) kg/m2 and
97.2 (9.9) cm, respectively, among males (N = 5,048), and 40.8 (11.6) years, 24.4 (3.8) kg/m2, and 81.9 (9.9) cm, among
females (N = 351). The prevalence of overweight, obesity, current smoking, hypertension, hypercholesterolemia, and
diabetes were 55.0, 23.1, 37.1, 40.3, 75.0, and 7.4%, respectively, among males, and 23.7, 8.3, 45.0, 12.1, 59.5, and
0.6%, respectively, among females. In the initial 587 study participants who completed all imaging exams (94.5%
male), the prevalence of carotid plaque, femoral plaque, coronary calcium score >1 to 100, and coronary calcium
score >100 was 30.3, 56.9, 27.0, and 8.8%, respectively. 67.7% of study participants had at least one plaque in the
carotid or femoral arteries.
Discussion: Baseline data from the AWHS show a high prevalence of cardiovascular risk factors and of sublinical
atherosclerosis. Follow-up of this cohort will allow the assessment of subclinical atherosclerosis progression and the
link of disease progression to traditional and emergent risk factors.* Correspondence: eguallar@jhsph.edu
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Cardiovascular disease (CVD) is the first cause of death
worldwide, but there are substantial differences in its inci-
dence, prevalence and mortality across countries and eth-
nicities [1-3]. Spain, a Mediterranean country with low
rates of coronary heart disease (CHD) compared to other
Western countries [4-7], has a paradoxical high prevalence
of traditional cardiovascular risk factors, including dyslipi-
demia, hypertension, smoking, and diabetes [5,6,8-11].
Furthermore, Spain is experiencing a severe epidemic of
overweight/obesity [12,13] that will likely increase the rate
of CHD and other obesity-related pathologies. The rea-
sons for the discrepancy between the risk factor profile
and the incidence of CHD in Spain are unclear and de-
serve additional study [14]. In addition, there is substantial
interest in understanding how a population-wide increase
in adiposity affects atherosclerosis and cardiovascular end-
points in a Western country with relatively low back-
ground levels of CHD.
Recent advances in imaging techniques provide a
unique opportunity to understand the relation between
risk factors and subclinical CVD at the population level.
Calcium coronary scoring increases risk discrimination
compared to risk equations based on traditional cardio-
vascular risk factors [15]. Moreover, carotid [16] and aortic
ultrasound scans [17], and the ankle-brachial blood pres-
sure index [18] provide added information on the pres-
ence of subclinical atherosclerosis in non-coronary
vascular territories [19]. In this context, the specific gen-
etic and environmental factors associated with the pres-
ence and the progression of subclinical atherosclerosis in
Mediterranean populations with high prevalence of risk
factors are still relatively unexplored, particularly in
middle-aged populations that may have developed sub-
clinical disease but not clinical symptoms.
In this paper, we describe the objectives, the methods
used for data collection and participant follow-up, and
the baseline characteristics of the Aragon Workers’
Health Study (AWHS), a longitudinal cohort study to
characterize the factors associated with metabolic abnor-
malities and subclinical atherosclerosis in a middle aged
population in Spain free of clinical CVD.
Methods/Design
Objectives of the Aragon workers’ health study
The AWHS was designed to evaluate the trajectories of
traditional and emergent CVD risk factors and their as-
sociation with the prevalence and progression of sub-
clinical atherosclerosis in a population of middle-aged
men and women in Spain. The study involves annual
evaluation of cardiovascular risk factors and clinical end-
points together with baseline and triennial blood and
urine sampling for biobanking and imaging of subclinical
atherosclerosis in a cohort of over 5,000 workers of alarge car assembly plant in Figueruelas (Zaragoza,
Spain). The study started in February 2009 and com-
pleted enrollment in December 2010. Active follow-up
of cohort participants will extend through 2020.
The specific aims of AWHS are to establish the research
infrastructure required for a longitudinal cohort study, in-
cluding setting up a biobank of repeated biological sam-
ples to conduct future assays in stored serum, plasma,
whole blood, urine, and DNA; to identify new genetic, be-
havioral, and environmental determinants of the progres-
sion of adiposity and of the development of metabolic
abnormalities and cardiovascular risk factors; to
characterize the prevalence and progression of subclinical
CVD through non-invasive imaging techniques and their
genetic, behavioral, and environmental determinants; to
interact with external investigators to promote the use of
the study database and stored materials for ancillary stud-
ies; and to disseminate the study findings to the scientific
community, to public health authorities, and to the gen-
eral public.
Sources of support
AWHS is funded through a collaborative agreement be-
tween the Instituto Aragonés de Ciencias de la Salud
(I +CS) of the regional Government of Aragón, the Na-
tional Center for Cardiovascular Research (CNIC) of the
Instituto de Salud Carlos III, and General Motors Spain.
The study was approved by the governing and scientific
boards of I +CS and CNIC, and by the management and
the workers’ representatives of General Motors Spain.
Study design and population
AWHS is a prospective, longitudinal cohort study based
on the annual health exams of the workers of the General
Motors Spain automobile assembly plant located in Fig-
ueruelas (Zaragoza, Spain). Each year, factory workers
undergo a standardized clinical exam. Starting in February
2009, factory workers were asked for consent to partici-
pate in AWHS by allowing use of their annual health
exam data, by completing additional questionnaires on
cardiovascular and lifestyle risk factors, by providing blood
and urine samples for the study biobank, and by partici-
pating in triennial exams to assess the presence of subclin-
ical atherosclerosis. The schedule of data collection in
AWHS is summarized in Figure 1. According to the study
protocol, workers who did not attend the annual exam
during the first year or who start working in the factory
after the study started will be offered the possibility of
entering the study in future exams. Workers are excluded
from the cohort if they have clinically overt CVD, or a
major clinical condition limiting survival to <3 years at
baseline. The study was approved by the central Institu-
tional Review Board of Aragón (CEICA). All study partici-
pants provided written informed consent.
ACTIVITY 2009/ 10 2011 2012 2013 2014 2015 2016 2017 2018 2019
Enrollment and 
informed consent X * * * * * * * * * 
Clinical exam X X X X X X X X X X 
Laboratory 













































clinical events X X X X X X X X X X 
Figure 1 Schedule of data collection, Aragon Workers Health Study.
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Data collection is organized around the annual medical
exam that the Medical Services of General Motors Spain
provide to all workers. The clinical exam follows stan-
dardized protocols using validated procedures and
instruments. Data collection at the annual medical
exams is conducted by the physicians and nurses of the
Medical Services of General Motors Spain, who under-
went training and standardization programs organized
by the study investigators. All study procedures are
described in the standard operating procedures. Compli-
ance with study procedures is routinely monitored and
deviations are corrected. The study conforms to the
ISO9001-2008 quality standard.
At each annual exam, study participants provide a
clinical history, including clinical events and hospitaliza-
tions over the past year and current medication use, and
undergo a physical exam, including anthropometry
(height, weight, and waist circumference), blood pressure
measurements and heart rate. Blood pressure is mea-
sured three consecutive times using an automatic oscil-
lometric sphygmomanometer OMRON M10-IT
(OMRON Healthcare Co. Ltd., Japan) with the partici-
pant sitting after a 5-min rest. Each participant also pro-
vided a sample of blood and urine after overnight (>8 h)
fasting for laboratory analyses and for biobanking.
Each year, one random third of study participants 40 –
55 years of age at baseline will be selected for subclinicalatherosclerosis imaging and for additional questionnaires of
cardiovascular and lifestyle factors, including the Spanish
validated versions of the Nurses’ Health Study and Health
Professionals’ Follow-up semi-quantitative food frequency
[20] and physical activity questionnaires [21], and the Cen-
ter for Epidemiological Studies – Depression (CES-D) scale
[22].Subclinical atherosclerosis imaging
Imaging of subclinical atherosclerosis is performed at
the AWHS Clinic located at the Hospital Universitario
Miguel Servet in Zaragoza, Spain. Calcium coronary
scoring is performed using non-contrast ECG gated pro-
spective acquisition by a 16 multidetector computed
tomography scanner (Philips). We will evaluate the pro-
gression/regression of calcium score as a continuous
variable. In addition, we will categorize coronary calcium
scores in 3 mutually exclusive groups: none; Agatston
score ≥1 to 100 and <75th percentile of the score in the
MESA population for the same age and sex [23]; and
Agatston score >100 or ≥75th percentile of the score in
the MESA population for the same age and sex. We
selected Agatston scores >100 or ≥75th percentile of the
age- and sex-specific distributions because these have
been the lower lower levels of coronary calcium asso-
ciated with mild increases in coronary heart disease
event rates [23].
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rotid plaque in both carotid arteries is determined using
an ultrasound system IU22 Philips. Ultrasound images are
acquired by linear high frequency 2-dimensional (2D) and
3-dimensional (3D) probes following the protocol of the
Bioimage Study [19]. Carotid plaque is defined as a focal
structure that protrudes into the lumen of the carotid ar-
tery at least 0.5 mm or ≥50% thicker than the surrounding
intima-media [24]. Intima-media thickness is considered
abnormal if it is ≥75th percentile of the age- and sex of
reference population [25].
Abdominal aorta aneurysms (AAA) are identified
using abdominal ultrasound with a linear transducer
[26] AAA are defined as localized dilatations of the ab-
dominal aorta ≥50% greater than the aortic diameter or
with a diameter ≥30 mm in cross-sectional view [24]. 2D
and 3D ultrasound imaging of the right and left femoral
and iliac arteries are also be performed by using linear
array transducers (Philips) [27]. Mean common femoral
intima-media thickness is calculated as the average of
the distances between the intima and media layers by
ultrasound in a 2-cm segment proximal to the bifur-
cation. Plaques are defined as in the carotid arteries. In
all cases plaques are recorded in both longitudinal and
transverse planes to take into consideration circumferen-
tial asymmetry.
The ankle-brachial index is calculated from resting
blood pressure measurements in the brachial arteries in
both arms and the posterior tibial and dorsalis pedis arter-
ies in both legs. We will consider abnormal an ankle-
brachial index ≤0.9 in at least one leg.
In AWHS, imaging techniques are applied to study
participants who are 40–55 years old at baseline. Ultra-
sound measures of the carotid, aortic, femoral and iliac
arteries and ankle-brachial blood pressure index are
measured in a random third of eligible participants each
year during years 2–4 of the study, and then repeated in
years 5–7 and 8–10 of the study. Coronary calcium will
be measured in years 2–4 of the study in a random third
of eligible participants each year and then repeated in
years 8–10 of the study. For each eligible participant, we
will thus be able to study the progression/regression of
subclinical atherosclerosis over 6 years of follow-up.
Laboratory analysis
Each year, study participants provide a blood and urine
samples after overnight fasting. A battery of laboratory
tests is performed annually in all workers at the laboratory
of the Medical Services of General Motors Spain. Fasting
serum glucose, triglycerides, total cholesterol and HDL-
cholesterol are measured by spectrophotometry (Chemical
Analyzer ILAB 650, Instrumentation Laboratory), serum
apolipoproteins AI and B by kinetic nephelometry
(Immunochemistry Analyzer IMMAGE 800, BeckmanCoulter), and fasting serum insulin by immunoenzymatic
chemiluminiscence (Access Immunoassay System, Beck-
man Coulter). Whole blood HbA1c is measured by
reverse-phase cationic exchange chromatography and
quantification by double wave-length colorimetry quantifi-
cation (Analyzer ADAMS A1c HA-810, Arkray Factory).
AWHS participates in two external quality control
programs: the national quality control program of the
Spanish Society for Clinical Chemistry (SEQC) for glu-
cose, triglycerides, total cholesterol, HDL-cholesterol,
apolipoprotein A1, and apolipoprotein B, and insulin,
and an international quality control program by BIO-
RAD for glucose, total cholesterol, and HDL-cholesterol.
Blood and urine samples are processed the same day
of extraction. Biological samples are stored from all co-
hort participants at baseline and for the one-third sub-
sample selected for imaging techniques each year. For
biobanking, about 15 ml of EDTA blood and 5 ml of
blood without anticoagulant for serum preparation are
fractionated into plasma, serum and whole blood and
stored in 1 ml dot-coded metal-free cryotubes at −80 °C.
Spot (casual) urine samples are also collected and stored
in 5 ml vials at −80 °C. Genomic DNA is extracted from
peripheral blood cells by use of commercial reagents
(FlexiGene DNA Kit, QIAGEN, USA). DNA purity and
concentration is determined by absorbance at 260 nm
(A260) and 280 nm (A280) using Nanovue (GE Health-
care, Munich Germany). DNA is stored in 0.3 ml vials at
−80 °C. Biological specimens for each participant are
stored in two geographically separated repositories.
Risk factor definition
Definitions of cardiovascular risk factors were based on
European Guidelines [28,29]. Hypertension was defined as
a measured blood pressure ≥140/90 mmHg (130/80 in
participants with diabetes) or current use of antihyperten-
sive medication. Hypercholesterolemia was defined as a
total cholesterol level ≥190 mg/dL (4.9 mmol/L) or
current use of lipid lowering medication. Diabetes was
defined as a diagnosis of diabetes in the clinical record,
current use of antidiabetic medication, a fasting serum
glucose ≥126 mg/dL (7.0 mmol/L), or an HbA1c ≥6.5%
[30].
Cohort follow-up
Follow-up of study participants is based primarily on the
annual medical exams at the factory. In addition to these
exams, the Medical Services of General Motors Spain rou-
tinely collect information on any clinical or health-related
event occurring to the workers during the study period.
Furthermore, an Absenteeism Center at General Motors
Spain tracks medical leaves or disabilities of all workers.
Finally, when workers who have been on medical leave for
>30 days return to work, they have to undergo a
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to collect information on the possible causes and sequelae
of the process responsible for the medical leave. All
diagnosis collected through the Medical Services or the
Absenteeism Center are revised and coded according to
standardized criteria by the study Endpoints Committee.
For workers who discontinue employment during the
study period, we will register the reason for discontinu-
ation (e.g. retirement) and its possible relation to health
events, and we will offer study participant the possibility
of continuing the annual exams and the triennial evalua-
tions of subclinical atherosclerosis at the AWHS Clinic
located in the Hospital Miguel Servet in Zaragoza, Spain.
Statistical methods
AWHS data are integrated in a relational database that
also provides support to the study biobank and the study
research and dissemination processes. Database manage-
ment and related processes, including anonymization,
security, back-ups, documentation, and data checks and
corrections, are documented in detail. The descriptive
analyses of baseline data presented in this paper are
based in means and standard deviations for continuous
variables and count and proportions for categorical vari-
ables. Statistical analyses were performed using Stata
version 11.
Results
Between February 2009 and May 2010, 5,775 workers
attended the annual clinical exam, of whom 5,456 (94.5%)Employees of GM assembly plant in 
Figueruelas (Zaragoza, Spain) in 2009* 
(N = 7,200) 
Employees attending a routine health exam 
during 02/2009 – 05/2010
(N = 5,806) 
Employees included in this report
(N = 5,400) 
Study participants 40 – 55 years of age 
eligible for subclinical atherosclerosis 
imaging (N = 3,584) 
Figure 2 Flowchart of study participants, Aragon Workers Health Studconsented to participate in the study (Figure 2). After ex-
clusion of 56 participants with prevalent CVD, the final
sample size was 5,400. Most participants were involved in
production jobs (manufacturing and assembly of automo-
bile pieces and components) from four areas: presses, car
body, painting, and final assembly. Other occupations
included maintenance (plumbing, electricity, electronics,
etc.), quality control (process laboratory and quality assur-
ance), movement of materials, and administrative work.
Most workers were involved in manual (blue collar) jobs
(86.5% of men and 60.5% of women).
Among males, the average (SD) age, body mass index,
and waist circumference were 49.3 (8.7) years, 27.7 (3.6)
kg/m2 and 97.2 (9.9) cm, respectively (Table 1). The pro-
portion of male participants who were overweight, obese,
and current smokers were 55.0, 23.1, and 37.1%, respect-
ively. The average systolic and diastolic blood pressure
were 127.0 (14.7) and 83.8 (10.1) mmHg, with a preva-
lence of hypertension of 40.3%. The average levels of total
cholesterol, HDL-cholesterol and triglycerides were 212.4
(37.6), 52.4 (11.0), and 148.8 (106.1) mg/dL, respectively,
with a prevalence of hypercholesterolemia of 75.0%. The
prevalence of diabetes was 7.4%.
Among females, the average (SD) age, body mass index,
and waist circumference were 40.8 (11.6) years, 24.4 (3.8)
kg/m2 and 81.9 (9.9) cm, respectively (Table 1). The pro-
portion of female participants who were overweight,
obese, and current smokers were 23.7, 8.3, and 45.0%,
respectively. The average systolic and diastolic blood
pressure were 111.4 (13.2) and 76.4 (9.5) mmHg, with aExclusions 
• Did not consent (N = 350) 
• Prevalent CVD  (N = 56) 
y.
Table 1 Aragon’ Workers Health Study (AWHS) baseline characteristics, 2009 – 2010
Men (N=5,048) Women (N=351)
N Mean (SD) or N (%) N Mean (SD) or N (%)
Age (y) 5,048 49.3 (8.7) 351 40.8 (11.6)
Height (cm) 5,031 171.5 (6.5) 351 161.3 (6.9)
Weight (kg) 5,031 81.6 (11.6) 350 63.5 (10.2)
BMI (kg/m2) 5,014 27.7 (3.6) 350 24.4 (3.8)
Underweight 11 (0.2) 6 (1.7)
Normal 1,085 (21.6) 232 (66.3)
Overweight 2,759 (55.0) 83 (23.7)
Obese 1,159 (23.1) 29 (8.3)
Waist circ. (cm) 4,987 97.2 (9.9) 345 81.9 (9.9)
Systolic BP (mmHg) 4,892 127.0 (14.7) 337 111.4 (13.2)
Diastolic BP (mmHg) 4,892 83.8 (10.1) 337 76.4 (9.5)
Tot. cholesterol (mg/dL)* 5,048 212.4 (37.6) 351 204.3 (39.9)
HDL-cholesterol (mg/dL)* 5,048 52.4 (11.0) 351 66.5 (14.2)
Triglycerides (mg/dL) * 5,048 148.8 (106.1) 351 89.7 (75.5)
Glucose (mg/dL)* 5,048 98.3 (19.6) 351 91.2 (16.3)
Smoking habits 5,017 349
Never 1,796 (35.8) 146 (41.8)
Former 1,359 (27.1) 46 (13.2)
Current 1,862 (37.1) 157 (45.0)
Hypertension 4,918 1,982 (40.3) 338 41 (12.1)
Hypercholesterolemia 5,048 3,788 (75.0) 351 209 (59.5)
Diabetes 5,048 371 (7.4) 351 2 (0.6)
Note: AWHS included 5,400 participants; 1 participant with missing sex data is not included in the Table.
* To convert to mmol/L multiply cholesterol levels by 0.0259, triglyceride levels by 0.0113, and glucose levels by 0.0555.
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total cholesterol, HDL-cholesterol and triglycerides were
204.3 (39.9), 66.5 (14.2), and 89.7 (75.5) mg/dL, respect-
ively, with a prevalence of hypercholesterolemia of 59.5%.
The prevalence of diabetes was 0.6%.
The initial 587 study participants who completed all
imaging exams (94.5% male) had an average (SD) age of
50.9 (3.6) years. The prevalence of carotid plaque, fem-
oral plaque, coronary calcium score >1 to 100, and ofTable 2 Prevalence of subclinical atherosclerosis in the
initial 587 AWHS participants completing all imaging
procedures
Age 40 – 50 Age 50 – 56 Overall
Age, years 47.0 (2.5) 52.9 (2.5) 50.9 (3.6)
Carotid plaque 46 (18.5) 194 (35.7) 240 (30.3)
Femoral plaque 101 (39.6) 317 (56.0) 418 (50.9)
Coronary calcium
Agatston score >1 to 100 48 (20.0) 159 (30.5) 207 (27.2)
Agatston score >100 8 (3.3) 59 (11.3) 67 (8.8)
Values in the Table are number (%), except for age [mean (SD)].coronary calcium score >100 was 30.3, 56.9, 27.0, and
8.8%, respectively. 67.7% of study participants had at
least one plaque in the carotid or femoral arteries
(Table 2).Discussion
In AWHS, we recruited a cohort of working middle age
men and women with a high prevalence of traditional
risk factors and of subclinical atherosclerosis but with a
low prevalence of overt CVD. At baseline, the AWHS
population showed a high prevalence of practically all
cardiovascular risk factors, and particularly of over-
weight and obesity. While there is no nationally repre-
sentative study of the prevalence of cardiovascular risk
factors in Spain, pooled analyses of local population-
based studies have also identified a high prevalence of
cardiovascular risk factors in the general population in
Spain (Table 3) [5,6,8-10].
The high prevalence of cardiovascular risk factors in
the AWHS population, particularly among men, is also
consistent with other studies of worker populations in
Spain [31-36]. Among workers at a different car
Table 3 Prevalence of traditional cardiovascular risk factors in large population studies in Spain
Study ERICE [9]* DARIOS [10] Sánchez-Chaparro et al [31].
Population Eight cross-sectional studies
representative of the general
adult population of the study’s target area
Studies representative of the
general adult population
of the study’s target area
Cross-sectional study health
insurance company
Period of data collection 1992 – 2001 2000 – 2009 2004 – 2005
Age range (years) 45 – 64 35 – 74 16 – 74
Sample size
Men 2,782 13,425 158,593
Women 3,412 15,462 58,321
Current smoking (%)
Men 38.6 33.0 51.3
Women 6.5 21.0 43.8
Hypertension (%)
Men 49.0 47.0 27.0
Women 50.3 39.0 8.8
Hypercholesterolemia (%)**
Men 59.8 81.0 48.7
Women 59.6 79.0 40.6
Diabetes (%)
Men 2.3 16.0 3.0
Women 1.1 11.0 0.6
Obesity (%)
Men 15.9 29.0 18.3
Women 13.3 29.0 8.0
* The ERICE Study included participants >18 years old; data in the present table is restricted to participants 45 to 64 years old.
** Total cholesterol >200 mg/dL (5.2 mmol/L) in the ERICE Study and in the study by Sánchez-Chaparro et al., and >190 mg/dL (4.9 mmol/L) in the DARIOS Study.
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at least one cardiovascular risk factor. In a large sample
of over 200,000 workers enrolled in a mutual insurance
fund in 2004 – 2005 (average age 36.4 years) [31], the
prevalence of smoking, overweight/obesity, hypertension,
hypercholesterolemia, and diabetes were 51.3, 63.1, 27.0,
48.7, and 3.0%, respectively, in men, and 43.8, 29.2, 8.8,
40.6, and 0.6%, respectively, in women. Similarly, in the
MESYAS Registry [34], the prevalence of workers who
were current smokers or who had at least one metabolic
abnormality were 51.4 and 65.5%, respectively. These
high levels of cardiovascular risk factors occurred among
relatively young populations under regular medical
supervision, highlighting the need for non-medical,
population-based approaches to cardiovascular risk con-
trol in these populations [37].
The high prevalence of cardiometabolic risk factors in
the AWHS population is likely a consequence of the
high prevalence of overweight/obesity. While there are
no systematic health surveys with comparable measures
of body mass index in Spain that allow for a detailed
characterization of the obesity epidemic in the country
[11], available data indicate that overweight/obesity hasbecome a major health problem in Spain [11-13]. In the
DARIOS Study, for instance, the average prevalence of
overweight/obesity in population based studies con-
ducted in Spain during 2000 – 2009 was 79% in men
and 65% in women [10]. Survey data based on self-
report suggest that the average body mass index of the
Spanish population has increased continuously at least
since the late 1980s and that the rate of growth has still
not leveled off [12]. Indeed, the Spanish and Greek cen-
ters had the highest prevalence of obesity of all centers
participating in the European Prospective Investigation
into Cancer and Nutrition (EPIC) Study [38]. The high
prevalence of overweight/obesity threatens the privileged
situation of Spain in terms of CVD incidence [14]. Ad-
vancing the understanding of the link between obesity,
cardiometabolic abnormalities and subclinical athero-
sclerosis is a major objective of the AWHS, well-suited
to the high prevalence of excess adiposity in this
population.
The AWHS uses a combination of non-invasive techni-
ques, modeled after the HRP Bioimage study [19], to iden-
tify subclinical atherosclerosis. In the initial 587 cases, we
found a higher prevalence of sublinical atherosclerotic
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teries. In addition, the presence of carotid and femoral
plaque was more common than the presence of coronary
calcium. The use of ultrasound to identify atherosclerosis
in the femoral arteries is significant innovation in AWHS
compared to other cohorts. A comparison of AWHS to
other landmark cohorts using non-invasive cardiovascular
imaging [19,39-42] is available in Table 4. Coronary cal-
cium scoring is the only novel cardiovascular biomarker
that markedly adds discriminative power to risk scores
based on traditional risk factors [15,43]. Carotid IMT is
the most commonly used ultrasound parameter to assess
subclinical atherosclerosis. Its usefulness has been limited
by operator-dependency and high within subject variabil-
ity [16], but the use of internal carotid artery maximum
IMT or presence of plaque instead of average IMT may
improve risk discrimination [44]. As in the HRP Bioimage
Study, we will use a 3D ultrasound probe that may have a
higher sensitivity for identifying carotid artery plaque
compared to 2D IMT imaging. In the AWHS we will also
perform abdominal and inguinal ultrasound scans to iden-
tify abdominal aortic aneurisms and iliac and femoral ath-
erosclerotic plaques. Repeated ultrasound scans every
3 years and calcium coronary scans after 6 years will allow
for a detailed characterization of the natural history of ath-
erosclerosis in study participants and for the identification
of novel determinants of its progression.
The AWHS provides an excellent opportunity to
evaluate cardiometabolic factors and subclinical athero-
sclerosis in a middle-age Mediterranean population with
high levels of overweight/obesity. Compared to other
studies, the availability of annual follow-up visits of
study participants will allow for a detailed evaluation of
the trajectories of cardiometabolic parameters and sub-
clinical atherosclerosis and their behavioral, environ-
mental, and genetic determinants. The high response
rate observed is a reflection of the long-standing collab-
oration between study investigators and personnel of the
Medical Services of General Motors Spain. Consistent
with previous collaborations of the research team, we
anticipate a high follow-up rate. In addition, although
the design of the AWHS has focused on cardiometabolic
risk factors because of their high impact in this popula-
tion, the cohort design of the AWHS will accommodate
the simultaneous study of other health issues. Because of
the annual study visits, the study is also well suited to
incorporate ancillary studies or tests that allow for the
evaluation of novel hypotheses.
As in any study, the findings of AWHS will be affected
by a variety of limitations. The main threat of losses to
follow-up corresponds to retiring workers and to work-
ers who stop working due to health issues. Whenever
workers terminate employment, we will register the rea-
sons and will invite participants to follow-up visits at theAWHS clinic at the Hospital Miguel Servet in Zaragoza,
Spain. In addition to selection biases, two factors will
limit the generalizability of the study. First, the AWHS is
based on a working population, and the findings may
not apply to non-working groups. The inclusion of
workers in the study, however, does not affect the attain-
ment of the main objectives of the study as the disease
processes evaluated in the study are not restricted to
specific occupations. Second, the study population is
composed largely, although not exclusively, of men,
reflecting the sex distribution in the factory. As a conse-
quence, AWHS will not be able to study cardiometabolic
risk factors that affect differentially men and women.
In spite of its limitations, AWHS will provide novel in-
formation on the distribution and trajectories of risk fac-
tors and subclinical CVD in a population with a high
prevalence of underlying risk factors but still with a low
prevalence of clinical CVD. We expect to identify trajec-
tories of risk factors that will provide hints for the con-
trol of the progression of early atherosclerosis and thus
minimize the burden of disease in later years of life.
Follow-up of this cohort will also allow the assessment
of subclinical atherosclerosis progression and the link of
disease progression to traditional and emergent risk
factors.
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